<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767947</url>
  </required_header>
  <id_info>
    <org_study_id>V01-LUZB-401</org_study_id>
    <nct_id>NCT02767947</nct_id>
    <nct_alias>NCT02491112</nct_alias>
  </id_info>
  <brief_title>Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis</brief_title>
  <official_title>A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and
      Efficacy of Product 33525 in Pediatric Subjects with Tinea Corporis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 8, 2016</start_date>
  <completion_date type="Actual">September 22, 2016</completion_date>
  <primary_completion_date type="Actual">June 29, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of circulating plasma levels of Luliconazole in subjects who have tinea corporis.</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Tinea Corporis</condition>
  <arm_group>
    <arm_group_label>Luliconazole Cream 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vehicle Cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luliconazole Cream 1%</intervention_name>
    <description>Cream</description>
    <arm_group_label>Luliconazole Cream 1%</arm_group_label>
    <other_name>Product 33525</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Cream</intervention_name>
    <description>Vehicle Cream</description>
    <arm_group_label>Vehicle Cream</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Subjects (or legal guardian/caregiver) with the ability and willingness to sign a
             written informed consent and/or assent (age appropriate).

          -  Subject of either gender must be at least 2 years to &lt; 18 years of age (2 to 17 years,
             inclusive).

          -  Subjects with a clinical diagnosis of tinea corporis characterized by clinical
             evidence of a tinea infection (at least moderate erythema, mild scaling, and moderate
             pruritus)

          -  Subjects must be in good general health and free of any disease that in the
             Investigator's opinion might interfere with the study evaluations.

          -  Subjects/caregiver must be able to communicate, be able to understand the study
             procedures, and be willing to comply with the study requirements.

        Key Exclusion Criteria:

          -  Subjects with active atopic or contact dermatitis in the area to be treated.

          -  Subjects with severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin
             infection.

          -  Female subjects who are pregnant and/or nursing or planning a pregnancy during the
             course of the trial. Subjects who test positive for pregnancy after start of test
             treatment will be discontinued from test treatment but will be followed for safety
             purposes.

          -  Subjects who are immunocompromised (due to disease, e.g., HIV or medications).

          -  Subjects who have a recent history of or current drug or alcohol abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anya Loncaric</last_name>
    <role>Study Director</role>
    <affiliation>Valeant Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Valeant Site 03</name>
      <address>
        <city>San Cristobal</city>
        <zip>91000</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 01</name>
      <address>
        <city>Santo Domingo</city>
        <zip>10700</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 02</name>
      <address>
        <city>San Pedro Sula</city>
        <zip>CT1100</zip>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>Honduras</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <disposition_first_submitted>December 13, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>December 13, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 15, 2017</disposition_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

